|
業務類別
|
Biotechnology |
|
業務概覽
|
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two ormore lines of antihypertensive medication or resistant hypertension, typically including a diuretic. |
| 公司地址
| 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087 |
| 電話號碼
| +1 888 378-6240 |
| 傳真號碼
| -- |
| 公司網頁
| https://mineralystx.com |
| 員工數量
| 51 |
| Mr. Jon Congleton |
Chief Executive Officer and Director |
美元 580.00K |
09/04/2025 |
| Dr. David Rodman, M.D. |
Chief Medical Officer |
美元 520.00K |
12/02/2025 |
| Mr. Adam S. Levy |
Chief Financial Officer, Principal Accounting Officer and Secretary |
美元 500.00K |
12/02/2025 |
|
|
| Dr. Alexander M. Gold, M.D. |
Independent Director |
09/04/2025 |
| Ms. Daphne Karydas, M.B.A. |
Independent Director |
09/04/2025 |
| Mr. Glenn P. Sblendorio |
Chairman of the Board |
09/04/2025 |
| Dr. Srinivas Akkaraju, M.D.,PhD |
Independent Director |
09/04/2025 |
| Mr. Jon Congleton |
Chief Executive Officer and Director |
09/04/2025 |
| Dr. Derek DiRocco, PhD |
Independent Director |
09/04/2025 |
| Dr. Brian Taylor Slingsby, M.D.,PhD |
Independent Director |
09/04/2025 |
|
|
|
|
